Prevalence and predictors of early hypercalcemia after kidney transplantation: a nested case-control study within a cohort of 100 patients.
Chronic kidney disease–mineral and bone disorder
Cinacalcet
End-stage kidney disease
Hypercalcemia
Hyperparathyroidism
Kidney transplantation
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
08
05
2018
accepted:
05
08
2018
pubmed:
20
8
2018
medline:
18
6
2019
entrez:
20
8
2018
Statut:
ppublish
Résumé
Hypercalcemia (HC) after kidney transplantation (KTx) can deteriorate both graft and patient survival. However, HC as a clinical condition and its clinical significance after KTx remain unknown. We evaluated the prevalence and risk factors of early HC after KTx. We performed a nested case-control study using a cohort of 100 KTx patients. KTx patients were divided into the HC and normocalcemia (NC) groups based on the baseline serum-corrected calcium (cCa) levels (≥ 10.5 and < 10.5 mg/dL) within 1 year after KTx. Overall, the median value of maximum serum cCa level within 1 year after KTx was 10.1 (9.1-13.8) mg/dL. Of the 100 KTx patients within the cohort, 31 patients (31.0%) were classified as the HC group. The maximum serum cCa level was reached significantly earlier in the HC group compared with the NC group (2 vs. 4 months, p = 0.024). In univariate analysis, the risk factors of early HC after KTx were dialysis duration ≥ 10 years, serum cCa level the day before KTx, and cinacalcet administration before KTx. Among these risk factors, serum cCa level the day before KTx and cinacalcet administration before KTx were identified as significant independent risk factors of early HC after KTx in multivariate analysis. One-third of the KTx patients presented early HC within 1 year after KTx. Early HC after KTx resulted from persistent hyperparathyroidism. Therapeutic strategies to manage HC after KTx must be established.
Sections du résumé
BACKGROUND
BACKGROUND
Hypercalcemia (HC) after kidney transplantation (KTx) can deteriorate both graft and patient survival. However, HC as a clinical condition and its clinical significance after KTx remain unknown. We evaluated the prevalence and risk factors of early HC after KTx.
METHODS
METHODS
We performed a nested case-control study using a cohort of 100 KTx patients. KTx patients were divided into the HC and normocalcemia (NC) groups based on the baseline serum-corrected calcium (cCa) levels (≥ 10.5 and < 10.5 mg/dL) within 1 year after KTx.
RESULTS
RESULTS
Overall, the median value of maximum serum cCa level within 1 year after KTx was 10.1 (9.1-13.8) mg/dL. Of the 100 KTx patients within the cohort, 31 patients (31.0%) were classified as the HC group. The maximum serum cCa level was reached significantly earlier in the HC group compared with the NC group (2 vs. 4 months, p = 0.024). In univariate analysis, the risk factors of early HC after KTx were dialysis duration ≥ 10 years, serum cCa level the day before KTx, and cinacalcet administration before KTx. Among these risk factors, serum cCa level the day before KTx and cinacalcet administration before KTx were identified as significant independent risk factors of early HC after KTx in multivariate analysis.
CONCLUSIONS
CONCLUSIONS
One-third of the KTx patients presented early HC within 1 year after KTx. Early HC after KTx resulted from persistent hyperparathyroidism. Therapeutic strategies to manage HC after KTx must be established.
Identifiants
pubmed: 30121799
doi: 10.1007/s10157-018-1627-6
pii: 10.1007/s10157-018-1627-6
doi:
Substances chimiques
Biomarkers
0
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-274Références
N Engl J Med. 1999 Dec 2;341(23):1725-30
pubmed: 10580071
Am J Transplant. 2005 Aug;5(8):1934-41
pubmed: 15996242
Transplant Proc. 2006 Mar;38(2):480-2
pubmed: 16549153
Kidney Int. 2007 Jan;71(1):31-8
pubmed: 17091124
Clin Transplant. 2007 Jul-Aug;21(4):558-66
pubmed: 17645720
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
J Nephrol. 2010 Nov-Dec;23 Suppl 16:S175-81
pubmed: 21170877
Int J Nephrol. 2011;2011:906832
pubmed: 21760999
Ther Apher Dial. 2011 Oct;15(5):481-7
pubmed: 21974702
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Semin Nephrol. 2013 Mar;33(2):191-203
pubmed: 23465505
Ther Apher Dial. 2013 Oct;17(5):551-6
pubmed: 24107283
World J Transplant. 2015 Dec 24;5(4):231-42
pubmed: 26722650
Int Urol Nephrol. 2016 Nov;48(11):1919-1925
pubmed: 27522659